Status:
COMPLETED
Effect of Low Dose Metronomic Chemotherapy in Metastatic Breast Cancer
Lead Sponsor:
Vastra Gotaland Region
Conditions:
Breast Cancer Metastatic
Chemotherapy Effect
Eligibility:
All Genders
18+ years
Brief Summary
Low dose metronomic chemotherapy (LDMC) in patients with metastatic breast cancer (MBC) is used as a palliative regiment with the aim to prolong and improve quality of life. The effect of LDMC is not ...
Eligibility Criteria
Inclusion
- Written and informed consent
- Breast cancer confirmed by histology
- Recurrence (local or distant) not possible to cure
- Measurable or evaluable disease
- Life expectancy of more than tree months
- ECOG (Eastern Cooperative Oncology Group) performance 0-2
- No or any lines of previous therapies for recurrent disease.
- Adequate contraception for patients of Child bearing age.
Exclusion
- Clinically significant cardiovascular disease
- Non healing wound, Active peptic ulcer or bone fracture
- Evidence of any other disease that puts the patient at high risk for treatment-related complications
Key Trial Info
Start Date :
March 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 30 2023
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04350021
Start Date
March 1 2019
End Date
October 30 2023
Last Update
January 17 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sahlgrenska University Hospital
Gothenburg, Västra Götaland County, Sweden, 405 83